Table 1.
Likelihood classification as FoR event | Primary outcome classification, with further details where relevant for mapping | Total participants in MITT population |
---|---|---|
Highly unlikely | Favorable | 292 |
Unlikely | Treatment change because of baseline DST results | 3 |
Treatment change because of investigator decisiona | 2 | |
Died during treatment or follow-up, culture converted when last seen, death not related to TB | 13 | |
Treatment changed following proven reinfection with exogenous strain of M. tuberculosis (using whole genome sequencing or other appropriate method) | 8 | |
Treatment change after adverse event | 7 | |
Lost to follow-up after 76 weeks, culture converted when last seen | 6 | |
Died within first 2 weeks of treatment, never achieved culture conversion | 1 | |
Lost to follow-up before 76 weeks (but after 40 weeks), culture converted when last seen | 4 | |
Possible | Lost to follow-up before 76 weeks, patient withdrew consentb | 8 |
Treatment changed after patient withdrew consent for study medicationc | 4 | |
Died at 8 weeks having not yet achieved culture conversion, death not related to TB | 2 | |
Treatment changed after loss to follow-up or poor adherence, with no positive bacteriology to suggest treatment failure | 2 | |
Probable | Died during treatment, probably related to TB | 3 |
Both positive and negative cultures within week 132 analysis window when last seend | 2 | |
Death 27 weeks after randomization, culture positive when last seen | 1 | |
Relapse after treatment, signs and symptoms with limited bacteriology | 1 | |
Reversion on treatment, signs and symptoms with limited bacteriology | 1 | |
Definite | Treatment changed following bacteriological reversion on treatment | 14 |
Treatment changed following bacteriological relapse after treatment | 5 | |
Died following bacteriological reversion on treatment | 2 | |
Lost to follow-up before 76 weeks following bacteriological reversion on treatment | 1 | |
Treatment changed after failure to achieve culture conversion | 1 |
aTreatment change so that participant could receive same treatment as young child (n = 1) or following a positive pregnancy test result (n = 1)
bReason for withdrawal of consent was due to adverse event (n = 4), or reason unknown (n = 4). All but one withdrew consent during the intensive phase of treatment; the participant that was an exception was initially lost to follow-up from the intensive phase and subsequently returned and then withdrew consent
cReason for withdrawal of consent was due to adverse event (n = 2), or reason unknown (n = 2)
dResults of m TB strain genotyping showed same strain as baseline (n = 1) and no comparison possible (n = 1)